Spyre Therapeutics, Inc. · NASDAQ:SYRE
The Vanguard Group reported a 5.08% stake in Spyre Therapeutics, Inc. (Schedule 13G)
Event Jun 30, 2025 · Filed Jul 29, 2025
The Vanguard Group reported a 5.08% stake in Spyre Therapeutics, Inc., 3,066,586 shares, as a passive investor on Jun 30, 2025. Filed Jul 29, 2025 (Schedule 13G).
- Stake
- 5.08%
- Shares
- 3,066,586
- Intent
- Passive
- What changed
- Crossed above 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| The Vanguard Group | 5.08% | 3,066,586 |
Source
Related
- Spyre Therapeutics, Inc.
- The Vanguard Group
- Spyre Therapeutics, Inc. shareholders
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026